Skip to main content
Top
Published in: Familial Cancer 1/2023

Open Access 20-05-2022 | Breast Cancer | Short Communication

Truncating TINF2 p.Tyr312Ter variant and inherited breast cancer susceptibility

Authors: Susanna Koivuluoma, MSc, Sandra Vorimo, BSc, Tiina M. Mattila, PhD, Anna Tervasmäki, PhD, Timo Kumpula, MSc, Outi Kuismin, MD, PhD, Robert Winqvist, PhD, Jukka Moilanen, MD, PhD, Tuomo Mantere, PhD, Katri Pylkäs, PhD

Published in: Familial Cancer | Issue 1/2023

Login to get access

Abstract

TINF2 is a critical subunit of the shelterin complex, which protects and maintains the length of telomeres. Pathogenic missense and truncating TINF2 mutations are causative for dyskeratosis congenita (DC), a rare, dominantly inherited bone marrow failure syndrome characterized by mucocutaneous abnormalities and cancer predisposition. Recent reports indicate that specific TINF2 truncating mutations act as high penetrance cancer predisposition alleles outside DC context, including breast cancer in their tumor spectrum. Here, we have evaluated the role of germline mutations in TINF2 and other shelterin genes in inherited breast cancer susceptibility using exome sequencing data from 98 Northern Finnish breast cancer cases with indication of inherited disease predisposition as a discovery cohort. A single protein truncating variant, TINF2 p.Tyr312Ter, was identified in one of the cases (1/98), and four more carriers were observed in the subsequently genotyped unselected breast cancer cohort (4/1904). None of the carriers were reported to have DC. TINF2 p.Tyr312Ter resulted in stable short form of mRNA transcript, and normal telomere length has been indicated by a recent report. Although recurrent in cases (total of 5/2095), TINF2 p.Tyr312Ter is also present in Finnish population controls (8/12,517), and the observed 4-fold higher frequency in cases falls at most into the range of moderate breast cancer risk alleles (OR 3.74, 95% CI 1.22–11.45, p = 0.029). Current results indicate that not all TINF2 truncating variants are high cancer risk alleles and add further evidence that different TINF2 mutations can have very diverse effects on the disease phenotype.
Appendix
Available only for authorised users
Literature
Metadata
Title
Truncating TINF2 p.Tyr312Ter variant and inherited breast cancer susceptibility
Authors
Susanna Koivuluoma, MSc
Sandra Vorimo, BSc
Tiina M. Mattila, PhD
Anna Tervasmäki, PhD
Timo Kumpula, MSc
Outi Kuismin, MD, PhD
Robert Winqvist, PhD
Jukka Moilanen, MD, PhD
Tuomo Mantere, PhD
Katri Pylkäs, PhD
Publication date
20-05-2022
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2023
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-022-00295-z

Other articles of this Issue 1/2023

Familial Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine